Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3350 | Respiratory symptoms, symptoms of anxiety and depression, and post-traumatic stress screening Wiki | 1.00 |
| drug1444 | Exercise capacity Wiki | 1.00 |
| drug2216 | Lung Function tests Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D003141 | Communicable Diseases NIH | 0.07 |
| D007239 | Infection NIH | 0.05 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
Coronavirus disease 2019 (COVID-19) is a respiratory tract infection caused by a newly emergent coronavirus (SARS-CoV-2) that can progress to severe disease requiring hospitalization and oxygen support in around14% of the cases and 5% require admission in intensive care unit. The medium and long-term impact in survivors of severe COVID-19 on lung function, exercise capacity and health-related quality of life remains to be determined.
Description: ratio obtained from measured values during spirometry
Measure: Forced expiratory volume in the first second/forced vital capacity Time: 6 monthsDescription: obtained from plethysmography (% of predicted)
Measure: Total lung capacity Time: 6 monthsDescription: obtained from single-breathe maneuver (% of predicted)
Measure: Lung diffusion capacity for carbon monoxide Time: 6 monthsDescription: distance walked during the test (m)
Measure: 6-minute walk test distance Time: 6 monthsDescription: scores range between 0 and 100 with higher scores indicating a better HRQoL
Measure: Short-form 36 questionnaire (SF-36) Time: 6 monthsDescription: ratio obtained from measured values during spirometry
Measure: Forced expiratory volume in the first second/forced vital capacity Time: 12 and 24 monthsDescription: % of predicted
Measure: Forced vital capacity Time: 6, 12 and 24 monthsDescription: ratio obtained from measured values during plethysmography
Measure: Residual volume/total lung capacity Time: 6, 12 and 24 monthsDescription: ratio obtained from measured values during plethysmography
Measure: Inspiratory capacity/total lung capacity Time: 6, 12 and 24 monthsDescription: obtained from body plethysmography
Measure: Airway resistance (Raw) Time: 6, 12 and 24 monthsDescription: obtained from single-breathe maneuver (% of predicted)
Measure: Lung diffusion capacity for carbon monoxide Time: 12 and 24 monthsDescription: obtained from Impulse oscillometry
Measure: Resistance at 20Hz and 5Hz (R5-R20) Time: 6, 12 and 24 monthsDescription: obtained from Impulse oscillometry
Measure: Reactance at 5Hz (X5) Time: 6, 12 and 24 monthsDescription: obtained from Impulse oscillometry
Measure: Resonant frequency (Fres) Time: 6, 12 and 24 monthsDescription: obtained from Impulse oscillometry
Measure: Reactance area (AХ) Time: 6, 12 and 24 monthsDescription: distance walked during the test (m)
Measure: 6-minute walk test distance Time: 12 and 24 monthsDescription: before 6-minute walk test
Measure: Pulse oximetry (SpO2) at rest Time: 6, 12 and 24 monthsDescription: at the end of 6-minute walk test
Measure: Pulse oximetry (SpO2) during exercise Time: 6, 12 and 24 monthsDescription: descriptive/qualitative questionnaire
Measure: Respiratory symptoms adapted from American Thoracic Society Questionnaire Time: 6, 12 and 24 monthsDescription: scores range between 0 and 100 with higher scores indicating a better HRQoL
Measure: Short-form 36 questionnaire (SF-36) Time: 12 and 24 monthsDescription: from incremental Cardiopulmonary exercise test (% of predicted)
Measure: Oxygen uptake at peak exercise Time: 6, 12 and 24 monthsDescription: from incremental Cardiopulmonary exercise test (L/L)
Measure: Minute-ventilation/carbon dioxide output during exercise Time: 6, 12 and 24 monthsDescription: from incremental Cardiopulmonary exercise test (measured with 10-point categorical Borg scale)
Measure: Dyspnea during exercise Time: 6, 12 and 24 monthsDescription: from incremental Cardiopulmonary exercise test (L and % of predicted)
Measure: Inspiratory capacity during exercise Time: 6, 12 and 24 monthsDescription: total score ranges from 0 to 63; higher score indicating higher anxiety
Measure: Beck Anxiety Inventory (BAI) Time: 6, 12 and 24 monthsDescription: total scores ranges from 0 to 63; higher score is worse
Measure: Beck Depression Inventory (BDI) Time: 6, 12 and 24 monthsDescription: 17-item, 5 likert-scale each item; higher score indicating more symptoms
Measure: Post-traumatic stress symptoms questionnaire Time: 6, 12 and 24 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports